为何胰岛素可及性问题仍未解决:美国与全球视角
胰岛素自1921年发现后在高收入国家广泛可用,但全球包括美国低收入人群仍难以获得。美国部分亚群糖尿病酮症酸中毒发生率仍高,胰岛素费用是主要诱因;全球层面1型糖尿病患儿主要死因是缺乏胰岛素可及性,撒哈拉以南非洲患儿预期寿命可低至1年。本文以「三腿凳」框架描述美国与全球胰岛素可及性不足。
要点
- 美国部分亚群糖尿病酮症酸中毒发生率仍高,胰岛素费用是主要诱因。
- 全球1型糖尿病患儿主要死因是缺乏胰岛素可及性。
- 撒哈拉以南非洲1型糖尿病患儿预期寿命可低至1年。
核心结论
- 胰岛素可及性不足是全球现象,不仅影响中低收入国家人群,也影响美国低收入人群。
研究设计与样本
- 本文为综述/观点文章,以美国与全球视角描述胰岛素可及性不足,并采用「三腿凳」框架(公共部门提供保护、私营部门提供负责任商业、多元部门提供社会联系)进行分析。
主要发现
- 美国部分亚群糖尿病酮症酸中毒发生率仍高,胰岛素费用是主要诱因。
- 全球层面1型糖尿病患儿主要死因是缺乏胰岛素可及性。
- 撒哈拉以南非洲1型糖尿病患儿预期寿命可低至1年。
- HIV/AIDS领域公共部门、私营部门和多元部门均对改善可及性发挥作用:民间社会提高意识并倡导治疗可及,政府提供国家与全球资金和应对,私营部门在压力下降低药价并制定扩大可及性项目。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Insulin was discovered in 1921 and soon became widely available in high-income countries. However, many people currently in need of this life-saving medicine are unable to access it. This is a global phenomenon, impacting not only populations of low- and middle-income countries but low-income populations in the U.S. In the U.S., the rate of diabetic ketoacidosis remains high in certain subpopulations, the cost of insulin being the main precipitating factor. On a global level the main cause of mortality for a child with type 1 diabetes is a lack of access to insulin, and in sub-Saharan Africa the life expectancy of a child with type 1 diabetes can be as low as 1 year. One lens for considering the issue of access to health and medicines is to consider society as a three-legged stool. In this paradigm, the role of the public sector is to provide "protections" to the population it serves; the private sector is made up of "responsible businesses" that supply many of the goods and services people need; and the plural sector comprises communities and not-for-profits providing the "social affiliations" that are needed. For HIV/AIDS, each of these "legs" played a role in improving access. Civil society raised awareness of the issue and advocated for access to treatment. Governments provided funding and responses both nationally and globally. Finally, the private sector played its role, under pressure from civil society and governments, in lowering the price of medicines and developing programs to expand access. Here, we use this framework to describe the shortcomings in access to insulin from a U.S. and global perspective.
引用
- Beran D, Hirsch IB, Yudkin JS, et al. Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective. Diabetes Care. 2018. PMID: 29784696. doi:10.2337/dc17-2123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。